BamSEC and AlphaSense Join Forces
Learn More

Citius Pharmaceuticals Inc.

NASDAQ: CTXR    
Share price (1/8/25): $3.71    
Market cap (1/8/25): $28.7 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 38 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.4
from 8-K 4 pages Promissory Note
12/34/56
EX-10.3
from 8-K 4 pages Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 August 12, 2024
12/34/56
EX-10.2
from 8-K 17 pages Amended and Restated Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 11 pages Amended and Restated Shared Services Agreement
12/34/56
EX-10.1
from 8-K 38 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 8-K 13 pages Form of Amended and Restated Shared Services Agreement
12/34/56
EX-10.3
from 425 13 pages Form of Amended and Restated Shared Services Agreement
12/34/56
EX-10.2
from 425 16 pages Form of Amended and Restated Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 16 pages Form of Amended and Restated Registration Rights Agreement
12/34/56
EX-10.1
from 425 12 pages Sponsor Support Agreement
12/34/56
EX-10.1
from 8-K 12 pages Sponsor Support Agreement
12/34/56
EX-10.1
from 10-Q 23 pages Patent and Technology License Agreement
12/34/56
EX-10.1
from 8-K 34 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 16 pages Amended and Restated Employment Agreement
12/34/56
EX-10.33
from 10-K 8 pages Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement
12/34/56
EX-10.32
from 10-K 3 pages Amendment to Amended and Restated License, Development and Commercialization Agreement
12/34/56
EX-10.31
from 10-K 86 pages Amended and Restated License, Development and Commercialization Agreement Between Eisai Co., Ltd. and Dr. Reddy’s Laboratories S.A. Dated as of February 26, 2018
12/34/56
EX-10.30
from 10-K 52 pages Asset Purchase Agreement by and Between Dr. Reddy’s Laboratories S.A., as Seller and Citius Pharmaceuticals, Inc., as Purchaser Dated as of September 1, 2021
12/34/56